NWRN — Newron Pharmaceuticals SpA Income Statement
0.000.00%
Last trade - 00:00
- CH₣135.64m
- CH₣170.69m
- €9.06m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.04 | 5.26 | 5.76 | 6.09 | 9.06 |
Cost of Revenue | |||||
Gross Profit | 5.61 | 4.96 | 5.64 | 5.65 | 8.59 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 27.9 | 23.3 | 18.1 | 19.4 | 20.7 |
Operating Profit | -20.9 | -18.1 | -12.4 | -13.3 | -11.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.2 | -19.6 | -14.9 | -17.5 | -16.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.2 | -21 | -14.9 | -17.5 | -16.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.2 | -21 | -14.9 | -17.5 | -16.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.2 | -21 | -14.9 | -17.5 | -16.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.13 | -1.1 | -0.835 | -0.98 | -0.905 |